Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Building the Future of CAR-T Therapy: Empowering Clinicians through an Outpatient Infrastructure Development Workshop
CAR-T therapy has revolutionized hematologic cancer treatment, but knowledge gaps and logistical barriers present challenges to successful outpatient administration. Critical gaps in integrating CAR-T evidence, designing outpatient infrastructure, and implementing effective strategies hinder optimal patient care and restrict CAR-T therapy accessibility. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Carmine DeLuca, Jessica Massey, Michael Beyer, Olalekan O. Oluwole, David L. Porter, Heather J Landau, Veronika Bachanova Tags: 199 Source Type: research

In Vivo Potency of Hematopoietic Stem Cells after Long-Term Storage at -80C in DMSO+HES Cryprotectant Mixture: Comparing Engraftment Kinetics and Efficacy Data in First and Second Autologous Stem Cell Transplantation in Myeloma
Two methods of hematopoietic stem cell (HSC) cryopreservation exist: 10% DMSO alone using rate-controlled freezing with storage in liquid nitrogen (LN2) and 5% DMSO/6%HES with ‘dump’ into and storage in mechanical freezers at -80C. Long-term storage at LN2 is clinically efficacious, but clinical data for long-term storage in DMSO/HES is lacking. To assess clinical benefit of HSC stored long term in DMSO+HES at -80C, we report on first and second autologous stem cell t ransplants (ASCT1 and 2) in patients undergoing sequential transplants for multiple myeloma (MM) using HSC stored>2 years. (Source: Biology of Blood and ...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Joseph Allan Norton, Loredana Campo, Patrick A. Hagen, Dr. Stephanie B. Tsai, Patrick J. Stiff Tags: 200 Source Type: research

Elevated Ferritin Prior to Collection and Mobilization May Predict Low Stem Cell Yield
Bone marrow transplantation requires collecting an adequate number of hematopoietic stem cells to ensure successful engraftment. Ferritin, a key iron storage protein and acute phase reactant, is routinely evaluated during pre-collection visits to assess for iron deficiency or overload and may impact stem cell capture. Physicians must anticipate difficulties in stem cell capture, and pre-collection ferritin levels may be helpful. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Charles Joseph Weeks, Danielle Bradshaw, Mohammad A H Mian, Anvay Shah, Katherine J Kim, Sujith Abbagoni, Anand P Jillella, Vamsi Kota Tags: 201 Source Type: research

Managing Damage - How to be Prepared: A Scale for Grading Cellular Therapy Product Integrity
Many cellular therapy products are cryopreserved as a part of processing, including all autologous cellular therapy products. Cryopreservation can cause products to become delicate and prone to damage during storage, retrieval, and transport, and this damage can affect the course of patient treatment.After a trend of damaged bags were seen in our institution, we recognized a need to communicate the scale of product bag damage in a more objective, standardized way to facilitate physicians making informed decisions and prepare infusion staff for the likelihood of bag leak and the possibility of cell loss. (Source: Biology of...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Jessika Barrera, Marco Torres Tags: 202 Source Type: research

Unveiling Immediate Pseudo-Progression with Epcoritamab in Lymphoma Treatment: Case Series Exploration
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype in the United States, with around 40% of patients experiencing relapse or resistance to initial chemoimmunotherapy. Despite attempts to improve outcomes with treatments like autologous hematopoietic stem cell transplant (AHCT) or CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, fewer than half achieve lasting remission. The recent FDA approval of CD20/CD3 BiTE therapies, such as Epcoritamab, has brought hope to heavily pretreated DLBCL cases. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Waled Bahaj, Mohammed Hegazi, Robert Emmons Tags: 203 Source Type: research

An Analysis of Visible Particulates Introduced to Liquid Pharmaceuticals By Disposable Syringes
Microplastics, as we know, are found in nearly all biological systems on Earth, as well as the food we eat and the water we drink. Even highly-regulated pharmaceutical disposables such as syringes, whose manufacturing quality controls aim to limit the incidence of particulates, may introduce microplastics to liquid drugs and substances. However, due to the nature of some cellular-based therapies, it may be difficult to notice these particulates. For example, the high concentration of cells in a final product may obscure the presence of translucent or nearly-clear particulates. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Henry Proctor Tags: 204 Source Type: research

Optimization of a Method for CD34-Selection of Cryopreserved Peripheral Blood Hematopoietic Cells
CD34-selections can minimize Graft Versus Host Disease (GVHD) in Hematopoietic stem cell transplantations (HCT) and boosts (HCB). Selections are most often done on fresh products; however, CD34-selections on cryopreserved hematopoietic progenitor cells (HPC) carries many logistical benefits. We optimized a method for CD34-selection on thawed, cryopreserved HPC apheresis collections (HPC-A). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Thane Kubik, Dustin Strasburg, Jacob Paulson, Jasmin Applen, Monica Klein, Margaret A DiGuardo, Eapen Jacob Tags: 205 Source Type: research

Abatacept with FluBu2: To Use or Not to Use
In 2021, the FDA approved using abatacept (ABA) for acute graft versus host disease (aGVHD) prevention in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (SCT) from a matched (MUD) or 1 allele-mismatched unrelated donor (MMUD), based on the phase II ABA2 study. In that study, there was no difference in engraftment or relapse between patients who received ABA and those who did not. However, this study included a significant number of young patients (median age (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Luis F Gonzalez-Mosquera, Mrs. Klodiana Neme, Nancy Mikulandric, Izabela Mazur, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, Shatha Farhan Tags: 206 Source Type: research

Long-Term Outcomes of Autologous Stem Cell Transplant with Thiotepa, Busulfan, and Cyclophosphamide Conditioning for Patients with Central Nervous System Lymphoma
Central nervous system lymphoma (CNSL) is associated with dismal outcomes and short survival. Treatment of CNSL involves high-dose chemotherapy followed by consolidative autologous stem cell transplant (ASCT). Thiotepa, busulfan and cyclophosphamide (TBC) conditioning improves progression-free survival in CNSL, but further data is needed to evaluate long-term toxicity and survival outcomes. We hereby report our experience in patients with primary and secondary CNSL who received TBC conditioning for ASCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Aseel Alsouqi, Zhexi Lu, Ziyu Huang, Frank Lieberman, Megan Mantica, Jan Drappatz, Rafic Farah Tags: 207 Source Type: research

Favorable Outcomes in Severe Aplastic Anemia Patients Undergoing Allo-HSCT with Fludarabine, Cyclophosphamide, and ATG Conditioning
Matched sibling donor (MSD) allogenic stem cell transplantation (allo-HSCT) is the standard of care curative treatment for young, fit patients with severe aplastic anemia (SAA). Several conditioning regimens have been studied, with Fludarabine (Flu)/Cyclophosphamide (Cy)/Anti-thymocyte globulin (ATG) or Cy/ATG demonstrating the best survival outcomes. Previous research reported 5-year survival probabilities of 91% for Flu/Cy/ATG, 91% for Cy/ATG, 80% for Cy ± Flu, and 84% for Bu/Cy (Bejanyan et al., 2019). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Reem Alasbali, Riad El Fakih, Ahmed Kotb Abdrabou, Naeem Chaudhri, Saud Alhayli, Fahad Alsharif, Amr Hanbali, Feras Alfraih, Marwan Shaheen, Mansour Alfayez, Alfadel Alshaibani, Abdulwahab Albabtain, Ahmad Alotaibi, AymanTusneem A SaadElhassan, Hadeel Sam Tags: 208 Source Type: research

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial
In allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk myeloid disorders, the intensity of the conditioning regimen correlates with the risk of relapse, but its benefit may be offset by its risk of toxicity.From 2017 to 2023, 31 patients with high-risk acute myeloid leukemia (AML, n=20) or myelodysplastic syndrome (MDS, n=5), or chronic myeloid leukemia (CML, n=3) in accelerated phase or blast crisis, were enrolled into a prospective phase II clinical trial of allogeneic HSCT using myeloablative TMI at 9Gy in combination with standard myeloablative fludarabine and targeted IV busulfan (FluBu4) chemother...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Lucas Maahs, Matthew Koshy, Karen Sweiss, Kang-hyun Ahn, Zhengjia Chen, Chukwuemeka Uzoka, Carlos Galvez, Paul Rubinstein, John Quigley, Santosh L Saraf, Ana Avila Rodriguez, Bulent Aydogan, Nadim Mahmud, Damiano Rondelli Tags: 209 Source Type: research

Clofarabine and High-Dose Melphalan Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation
We report results of our experience with a clofarabine-based RIC conditioning for adult patients with non-Hodgkin lymphoma and myeloid malignancies. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Sandy On, Walter Domingo, Edna Cheung, Laura Johnston Tags: 211 Source Type: research

Post-Transplant Cyclophosphamide (PTCY) Results in Remarkably Low Incidence of Chronic Graft-Versus-Host Disease in Unrelated or Matched Sibling Donor Stem Cell Transplantation without Compromising Immune Reconstitution and Graft-Versus-Leukemia Effect
PTCY was first applied in the haploidentical stem cell transplantation (SCT) setting and is gradually being used in mismatched unrelated or fully matched donor transplants. We prospectively tested this approach in SCT from matched or mismatched unrelated (MUD/MMUD) and matched sibling donors (MSD) to reduce the incidence of acute and especially chronic graft-vs-host disease (GVHD).From 01/2021 to 05/2023, 51 consecutive patients, aged 18-69 (median 52) years, received allogeneic SCT with PTCY for AML/MDS (n=36), NHL/CLL (n=2), primary myelofibrosis (n=2), CML (n=2), or ALL (n=9). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ifigeneia Tzannou, Ioannis Tsonis, Tatiana Tzenou, Aikaterini Souravla, Maria Katsareli, Natali El Gotmi, Ismini Darmani, Evridiki Theodorou, Maria-Eleni Karatza, Maria Garofalaki, Zoi Poulopoulou, Marina Papageorgiou, Soultana Tryfonidou, Panagiotis Siam Tags: 212 Source Type: research

Excellent Outcome Following Haplo-Identical and Unrelated Donor HSCT for Young Patients with Sever Aplastic Anemia Using Reduced Dose TBI and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis
Severe aplastic anemia (SAA) is a potentially fatal hematologic disorder that can be cured with hematopoietic stem cell transplantation (HSCT). Although the outcomes with HLA-identical siblings are favorable, the majority of patients lack suitable HLA-identical donors. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ayad Ahmed Hussein, Clinton Carroll, Noor Awni Ghanem, Bayan Majed Alaraj, Jennifer Domm, Tariq Ahmed Abdelghani, Meghann McManus, Dina Mohammad Abu Assab, Hadeel Hassan Alzoubi, Misty Evans, Haydar Frangoul Tags: 213 Source Type: research

Phase I Study of Bendamustine and Melphalan Conditioning Followed By Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma and B-Cell Lymphoma in Elderly Patients
High-dose chemo and autologous hematopoietic cell transplantation (AHCT) is an effective consolidation therapy in non-Hodgkin lymphoma (NHL) and multiple myeloma (MM); however, its use in elderly patients is limited by toxicity. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Gagan Raju, Gunjan L. Shah, Stephanie M. Lobaugh, Sean M. Devlin, Grashma Vadakkel, Stephen William Eng, Andrew Lin, Amethyst Saldia, Martin Donach, Danielle Engstler, Yetunde Aremu, Oscar B. Lahoud, Paul Hamlin, Michael Scordo, Miguel-Angel Perales, Crai Tags: 214 Source Type: research